Issue 10, volume 4, Supplement of Alz and Dementia: Journal of the Alz Association, Session 04-11-02, P273, entitled “The Safety and Tolerability of [TNF Inhibitor] in AD (STEADI-09): A Phase II Double Blind Randomised Placebo Controlled Trial”, principal investigator Clive Holmes MD, University of Southampton, Southampton, United Kingdom, contains the first double-blind, randomized, placebo-controlled data supporting the therapeutic efficacy of anti-TNF for treatment of AD. The abstract of this study (full-text here) published in this issue in July 2014.

A 2008 article in BBC News had previously discussed the favorable results of anti-TNF for treatment of AD in a study from TransBarrier® The article reported at the time that Clive Holmes MD was interested in taking on further research utilizing this treatment approach.